Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

There are two search modes available: simple and advanced. Simple search can include one or more words from the title, summary, keywords or full text, but does not allow the use of search operators. Advanced search allows to limit the number of search results by entering the search terms of different categories in the search window, as well as the use of Boolean search operators (AND, OR and AND NOT). In search results short formats of records are displayed and some data are displayed as links, which open a detailed description of the material (title link) or perform a new search (author or keyword link).

Help
Search in:
Options:
 


1011 - 1020 / 2000
First pagePrevious page9899100101102103104105106107Next pageLast page
1011.
1012.
1013.
Advances in diagnostics and management of gestational trophoblastic disease
Nuša Lukinovič, Eva Pavla Malovrh, Iztok Takač, Monika Sobočan, Jure Knez, 2022, review article

Published in DiRROS: 25.07.2024; Views: 274; Downloads: 174
.pdf Full text (519,32 KB)
This document has many files! More...

1014.
Cardiac myxoma : single tertiary centre experience
Polona Kačar, Nejc Pavšič, Mojca Bervar, Zvezdana Dolenc-Stražar, Vesna Zadnik, Matija Jelenc, Katja Prokšelj, 2022, original scientific article

Published in DiRROS: 25.07.2024; Views: 306; Downloads: 97
.pdf Full text (709,95 KB)

1015.
1016.
1017.
Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma
Špela Koršič, Nastja Levašič, Rok Dežman, Lara Anja Lešnik Zupan, Blaž Trotovšek, Rado Janša, Lojze Šmid, Peter Popović, 2022, original scientific article

Abstract: Background. Drug-eluting microsphere transarterial chemoembolization (DEM-TACE) is the standard of care in pa-tients with intermediate-stage hepatocellular carcinoma and ensures targeted and controlled cytotoxic and ischemic effects. Proper patient selection and optimized treatment techniques are associated with longer median survival. The aim of this single-institution retrospective study was to evaluate safety and efficacy of DEM-TACE under cone beam computed tomography (CBCT) control in patients with early and intermediate stagehepatocellular carcinoma.Patients and methods. A total of144 patients (mean age 67.9 ± 8.0 years, 127 males and 17 females) between February 2010 and December 2018 were studied. Microparticles of different dimensions according to two manufac-turers (diameter of 70–150 μm, 100–300 μm or 300–500 μm and 40-μm, 75-μm or 100-μm) were used and loaded with 50–150 mg of doxorubicin. The objective tumour response according to the modified Response Evaluation Criteria in Solid Tumours (mRECIST), the time to progression, adverse events and overall survival were (OS) evaluated.Results. In total, 452 procedures were performed (median, 3 per patient). Four (0.9% of all procedures) major com-plications were noted. Postembolization syndrome occurred after 35% of procedures. At the first imaging follow-up 2–3 months after first treatment, 91% of patients achieved an objective response. The median time to progression was 10.2 months (95% CI: 8.3-12.1 months). OS rates at 1, 2, 3, 4, and 5 years were 85%, 53%, 33%, 20% and 14%, respectively. The median survival time was 25.8 months (95% CI: 22.1–29.5 months). Conclusions. DEM-TACE under CBCT control in patients with early and intermediate stagehepatocellular carcinoma is a safe and effective method of treatment with high objective tumour response and survival rates.
Keywords: hepatocellular carcinoma, drug-eluting microspheres, doxorubicin
Published in DiRROS: 25.07.2024; Views: 401; Downloads: 161
.pdf Full text (1,34 MB)
This document has many files! More...

1018.
Crystalloids vs. colloids for fluid optimization in patients undergoing brain tumour surgery
Jasmina Markovič Božič, Božidar Visočnik, Polona Mušič, Iztok Potočnik, Alenka Spindler-Vesel, 2022, original scientific article

Abstract: Background. This randomised, double-blinded, single-centre study prospectively investigated the impact of goal directed therapy and fluid optimization with crystalloids or colloids on perioperative complications in patients un-dergoing brain tumour surgery. Main aim of the study was to investigate the impact of fluid type on postoperative complications.Patients and methods. 80 patients were allocated into two equal groups to be optimised with either crystalloids (n = 40) or colloids (n = 40). Invasive hemodynamic monitoring was used to adjust and maintain mean arterial pressure and cerebral oxygenation within the baseline values (± 20%) and stroke volume variation (SVV) ≤ 10%. Postoperative complications from different organ systems were monitored during the first 15 days after surgery. Hospital stay was also recorded.Results. Crystalloid group received significantly more fluids (p = 0.003) and phenylephrine (p = 0.02) compared to colloid group. This did not have any significant impact on perioperative complications and hospital stay, since no dif-ferences between groups were observed. Conclusions. Either crystalloids or colloids could be used for fluid optimization in brain tumour surgery. If protocol-ised perioperative haemodynamic management is used, the type of fluid does not have significant impact on the outcome.
Published in DiRROS: 25.07.2024; Views: 278; Downloads: 81
.pdf Full text (618,86 KB)

1019.
1020.
Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer
Marko Bitenc, Tanja Čufer, Izidor Kern, Martina Miklavčič, Sabrina Petrovič, Vida Groznik, Aleksander Sadikov, 2022, original scientific article

Abstract: Treatment of early-stage non-small cell lung cancer (NSCLC) is rapidly evolving. When introducing novelties, real-life data on effectiveness of currently used treatment strategies are needed. The present study evaluated outcomes of stage I–IIIA NSCLC patients treated with upfront radical surgery in everyday clinical practice, between 2010–2017. Data of 539 consecutive patients were retrieved from a prospective hospital-based registry. All diagnostic, treatment and follow-up procedures were performed at the same thoracic oncology centre according to the valid guidelines. The primary outcome was overall survival (OS) analysed by clinical(c) and pathological(p) TNM (tumour, node, metastases) stage. The impact of clinicopathological characteristics on OS was evaluated using univariable (UVA) and multivariable regression analysis (MVA). With a median follow-up of 53.9 months, median OS and 5-year OS rate in the overall population were 90.4 months and 64.4%. Five-year OS rates by pTNM stage I, II and IIIA were 70.2%, 60.21%, and 49.9%, respectively. Both cTNM and pTNM stages were associated with OS; but only pTNM retained its independent prognostic value (p = 0.003) in MVA. Agreement between cTNM and pTNM was 69.0%. Next to pTNM, age (p = 0.001) and gender (p = 0.004) retained their independent prognostic value for OS. The study showed favourable outcomes of resectable stage I–IIIA NSCLC treated with upfront surgery in real-life. Relatively low agreement between cTNM and pTNM stages and independent prognostic value of only pTNM, observed in real-life data, suggest that surgery remains the most accurate provider of the anatomical stage of disease and important upfront therapy.
Keywords: resectable NSCLC, upfront surgery, real-life data, overall survival, prognostic factors
Published in DiRROS: 25.07.2024; Views: 283; Downloads: 222
.pdf Full text (747,28 KB)
This document has many files! More...

Search done in 1.66 sec.
Back to top